Anavex Life Sciences Corp.
NASDAQ:AVXLBiotechnology
-$0.04 today
- Market cap
- $66.69M
- Beta
- 1.12
- P/E (TTM)
- -5.9
- EPS (TTM)
- -$0.45
Volume 1.06M
Average 1.39M
AVXL Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Anavex Life Sciences Corp.NASDAQ: AVXL
Accounts Receivables · Q1 FY2026 · quarter ended Dec 2025
Accounts receivables dips below year-ago levels
Q1 FY2026 accounts receivables of $35K (cash outflow) fell 67.6% year over year, behind the +72.7% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -34.9% a year.
Context
- Accounts receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -67.6% toward the trailing-twelve-month pace of +72.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 1.64M USD
- Year-over-year change
- +530.8%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 1.64M | +530.8% |
| FY2024 | 2024-09-30 | 260K | -46.3% |
| FY2023 | 2023-09-30 | 484K | -91.9% |
| FY2022 | 2022-09-30 | 5.94M | +238.7% |
| FY2021 | 2021-09-30 | (4.29M) | — |
Accounts Receivables vs competitors
How AVXL compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +72.7% is the 5th highest of 8, against a peer median of +100.0%.
- Over three fiscal years its annual growth of -34.9% compares with a peer median of +2.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $13.03M USD | -178.8% | — | 16.3% | |
| LTM Mar 2026 | $9.02M USD | +328.9% | — | 10.3% | |
| LTM Mar 2026 | $2.07M USD | +38.7% | +209.4% | — | |
| LTM Mar 2026 | $2M USD | +253.8% | -19.5% | 2.2% | |
| LTM Dec 2025 | $1.71M USD | +72.7% | -34.9% | — | |
| LTM Mar 2026 | $1.38M USD | +207.1% | — | 75.4% | |
| LTM Mar 2026 | $1.31M USD | -88.3% | — | 3.7% | |
| LTM Sep 2026 | $0 USD | — | — | — | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $0 USD | — | — | — |
| LTM Mar 2026 | €0 EUR | +100.0% | +2.4% | 0.0% | |
| Peer median (excluding AVXL) | — | +100.0% | +2.4% | 7.0% | |
Competitors are the stored peer set for AVXL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | (37.91M) | (47.98M) | (47.51M) | (43M) | (46.38M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.23M | 18.38M | 16.37M | 9.44M | 11.55M |
| Change in Working Capital | (706K) | 5.36M | 2.51M | 2.75M | (4.22M) |
| Accounts Receivables | (4.29M) | 5.94M | 484K | 260K | 1.64M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 751K | (914K) | 497K | 5.31M | (5.38M) |
| Other Working Capital | 2.83M | 331K | 1.52M | (2.81M) | (478K) |
| Other Non-Cash Items | 0 | 0 | 845K | 0 | 0 |
| Operating Cash Flow | (30.38M) | (24.24M) | (27.79M) | (30.81M) | (39.04M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 153.22M | 22M | 29.65M | 11.98M | 12.14M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 24K | (707K) | 29.65M | 11.98M | (2.71M) |
| Financing Cash Flow | 153.24M | 21.29M | 29.65M | 11.98M | 9.43M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 122.86M | (2.95M) | 1.87M | (18.84M) | (29.61M) |
| Free Cash Flow | (30.38M) | (24.24M) | (27.79M) | (30.81M) | (39.04M) |
Anavex Life Sciences Corp.
NASDAQ:AVXL
Intrinsic Alpha fair value
Locked
Current Price
$0.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.